Last reviewed · How we verify
Twice daily immunosuppression regimen
A twice-daily immunosuppressive regimen reduces immune system activity to prevent organ rejection or manage autoimmune conditions.
A twice-daily immunosuppressive regimen reduces immune system activity to prevent organ rejection or manage autoimmune conditions. Used for Organ transplant rejection prevention, Autoimmune disease management.
At a glance
| Generic name | Twice daily immunosuppression regimen |
|---|---|
| Sponsor | Washington University School of Medicine |
| Drug class | Immunosuppressive combination regimen |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
This regimen typically combines multiple immunosuppressive agents administered twice daily to achieve sustained suppression of T-cell and B-cell mediated immune responses. The specific mechanism depends on the constituent drugs, which commonly include calcineurin inhibitors, antiproliferative agents, and/or corticosteroids that work synergistically to prevent graft rejection or control autoimmune disease.
Approved indications
- Organ transplant rejection prevention
- Autoimmune disease management
Common side effects
- Infection
- Nephrotoxicity
- Hypertension
- Hyperglycemia
- Bone marrow suppression
Key clinical trials
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) (PHASE2)
- Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progression in Participants With Bilateral Lung Transplant (PHASE3)
- rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease (PHASE1, PHASE2)
- Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR (PHASE4)
- IS-free Treg HaploHCT (PHASE1)
- Treg Therapy in Subclinical Inflammation in Kidney Transplantation (PHASE1, PHASE2)
- Early Use of Long-acting Tacrolimus in Lung Transplant Recipients (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: